Looking back over the past 2 years, the pandemic continues to test all standards and norms associated with drug development, including timelines, regulatory processes and inspections, manufacturing, and supply chain management. Through strategic partnerships and outsourcing strategies, pharmaceutical and biotech companies are enabling acceleration through collaboration.
As we begin to look forward to the future of drug development, view a panel discussion examining new short- and long-term CDMO and supply chain strategies. Our panel, comprised of industry consultants and early development experts, discussed:
- Approaches for building your early development outsourcing strategy
- Considerations for vendor selection for pre-IND and phase-appropriate sourcing to mitigate supply chain disruption
- Global vs. local sourcing strategies – from drug discovery to analytical and biopharmaceutical testing to manufacturing
- Regulatory considerations for accelerating drug development